Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05514132
Other study ID # D5330C00017
Secondary ID
Status Active, not recruiting
Phase Phase 1
First received
Last updated
Start date September 23, 2022
Est. completion date April 1, 2025

Study information

Verified date May 2024
Source AstraZeneca
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a Phase 1, open-label study of ceralasertib given in combination with durvalumab in Chinese participants with advanced solid tumours. In each cohort, a monotherapy lead-in period (Cycle 0, duration of 7 or 14 days), prior to dosing with durvalumab, is added to investigate the PK profile and safety/tolerability of ceralasertib in Chinese participants. This study is designed to investigate and characterise preliminary safety, tolerability, and PK of ceralasertib in DLT-evaluable Chinese participants


Description:

Primary Objective: To assess the safety and tolerability of ceralasertib in combination with durvalumab in Chinese patients with advanced solid tumours refractory/resistant to prior SoC therapy or for which no appropriate SoC therapy exists. Secondary Objective: To characterise the PK profile of ceralasertib after single- and multiple-doses administration. To characterise the anti-tumour activity and efficacy of ceralasertib in combination with durvalumab in Chinese patients . This is a Phase 1, open-label study of ceralasertib given in combination with durvalumab in Chinese patients with advanced solid tumours.Results from this study will provide dose rationale for future investigations.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 14
Est. completion date April 1, 2025
Est. primary completion date October 20, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Signed written informed consent. 2. At least 18 years of age at the time of signing the ICF. 3. Histological or cytological confirmation advanced solid tumour with refractory/resistance to a prior line of anti-PD-1/PD-L1-containing therapy (received as monotherapy or in combination) or for which no SoC exists. 4. Ability to swallow oral medication intact and retain it. 5. ECOG/WHO performance status of 0 to 1. 6. Must have a life expectancy of at least 12 weeks. 7. Participant must have had a treatment-free interval of = 3 weeks from any prior therapy before the first dose of study treatment. 8. Body weight > 35 kg and no cancer-associated cachexia (eg, CTCAE Grade 2 or worse weight loss over the 3 months prior to the Screening Visit). 9. Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Exclusion Criteria: 1. Inadequate bone marrow reserve or organ function 2. As judged by the investigator, any evidence of uncontrolled intercurrent illness, that in the investigator's opinion makes it undesirable for the participant to participate in the study. 3. Spinal cord compression, leptomeningeal disease, or brain metastases, unless asymptomatic, treated, stable, and not requiring continuous corticosteroids 4. As judged by the investigator, any active disease or condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of oral therapy 5. History of another primary malignancy. 6. As judged by the Investigator, any evidence of severe or uncontrolled systemic diseases, active bleeding diatheses, renal transplant, or active infection including any patient known to have hepatitis B, hepatitis C, and HIV. 7. Known history of HIV infection. 8. Active cardiacvascular disease be consider as clinical significant. 9. Active or prior documented autoimmune or inflammatory disorders 10. Prior exposure to a CHK1 or ATR inhibitor. 11. As judged by the investigator, any unresolved treatment-related toxicities from previous anti-cancer therapy of CTCAE v5.0 Grade = 2 12. Any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment. 13. Participants must not have experienced a toxicity that led to permanent discontinuation of prior anti-PD-1 or anti-PD-L1 immunotherapy. 14. Participants must not have required the use of additional immunosuppression other than corticosteroids for the management of an AE, not have experienced recurrence of an AE if re-challenged 15. Participants with a known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients 16. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site). 17. Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions and requirements. 18. Previous enrolment in the present study. 19. For women only - currently pregnant (confirmed with positive pregnancy test) or breastfeeding.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Ceralasertib
Ceralasertib (AZD6738) is a potent, selective inhibitor of the serine/threonine-specific protein kinase, ATR, with good selectivity against other phosphatidylinositol 3-kinase-related kinase family members.
Durvalumab
Durvalumab is a human mAb of the immunoglobulin G 1 kappa subclass that blocks the interaction of PD-L1 (but not PD-L2) with PD-1 on T cells and CD80 (B7.1) on immune cells.

Locations

Country Name City State
China Research Site Beijing
China Research Site Shandong

Sponsors (1)

Lead Sponsor Collaborator
AstraZeneca

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary The number of subjects with dose-limiting toxicity, as defined in the protocol. Dose-limiting toxicity as described in the protocol that is not related to disease progression, intercurrent illness or concomitant medications and that, despite optional therapeutic intervention, meets protocol-defined criteria. From the first dose of study treatment Up to and including the end of cycle 1(each cycle is 28 days) .
Primary Safety and tolerability in terms of adverse events Number of subjects with adverse events as a measure of safety and tolerability including changes in vital signs, electrocardiograms (ECGs), safety and laboratory parameters From the first dose of study treatment until 28 days after the last dose.
Secondary Plasma ceralasertib concentration(Cmax) Observed PK parameters of ceralasertib Cycle 0 Day1 to Day7, Cycle1 Day1 and Cycle 1 Day 7 or Day 8. At the end of Cycle1(each cycle is 28 days)
Secondary Area under the plasma concentration versus time curve(AUC) Observed PK parameters of ceralasertib. Cycle 0 Day1 to Day7, Cycle1 Day1 and Cycle1 Day7 or Day8. At the end of Cycle1(each cycle is 28 days)
Secondary Overall response rate Antitumor activity by evaluation of tumor response assessments using RECIST 1.1 At screening and Every 8 weeks ±1 week relative to the start of therapy (Cycle 1 Day 1, each cycle is 28days) until objective disease progression as defined by RECIST version 1.1
Secondary Duration of Response Antitumor activity by evaluation of tumor response assessments using RECIST 1.1 At screening and Every 8 weeks ±1 week relative to the start of therapy (Cycle 1 Day 1, each cycle is 28 days) until objective disease progression as defined by RECIST version 1.1
Secondary Percentage Change in Tumour Size Antitumor activity by evaluation of tumor response assessments using RECIST 1.1 At screening and Every 8 weeks ±1 week relative to the start of therapy (Cycle 1 Day 1, each cycle is 28 days) until objective disease progression as defined by RECIST version 1.1
Secondary Progression Free Survival Antitumor activity by evaluation of tumor response assessments using RECIST 1.1 From start of treatment until the date of objective disease progression or death. (approximately 6 months).
See also
  Status Clinical Trial Phase
Terminated NCT04949425 - A Study to Assess the Safety and Tolerability of Adavosertib for Patients With Advanced Solid Tumours Phase 1
Not yet recruiting NCT05537051 - A Study of PM1021 (Anti-TIGIT) With or Without PM8001 (Anti-PD-L1/TGF-β) in Patients With Advanced Solid Tumours Phase 1
Completed NCT02579226 - A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors. Phase 1
Terminated NCT01668550 - A Phase I Study of AZD0424 Alone and in Combination in Advanced Solid Tumours Phase 1
Completed NCT01058538 - A Dose Finding Pharmacokinetic Study of the Tumour-targeting Human L19IL2 Monoclonal Antibody-Cytokine Fusion Protein in Patients With Advanced Solid Tumours Phase 1/Phase 2
Completed NCT02588105 - Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer Phase 1
Recruiting NCT03852823 - Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours Phase 1
Not yet recruiting NCT06380816 - A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer Phase 1/Phase 2
Completed NCT01585701 - Phase I Study of AT13148, a Novel AGC Kinase Inhibitor Phase 1
Completed NCT03101839 - Phase I Dose-Escalation Study of AZD4785 in Patients With Advanced Solid Tumours Phase 1
Completed NCT03150368 - Extended Use of ModraDoc006/r Phase 1
Active, not recruiting NCT02389842 - PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclib Phase 1
Terminated NCT01581060 - Phase I/II Dose-escalation Study to Investigate Safety and Pharmacokinetics/ Pharmacodynamics of WX-554 in Patients With Solid Tumours Phase 1/Phase 2
Terminated NCT04959266 - A Study to Assess the Effects of Itraconazole, Rifampicin, and Omeprazole on Pharmacokinetics of Adavosertib Phase 1
Completed NCT04462952 - Study of Adavosertib(AZD1775) in Japanese Patients With Advanced Solid Tumours Phase 1
Active, not recruiting NCT03518606 - Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours Phase 1/Phase 2
Completed NCT02430311 - The Pharmacokinetics and Safety of Olaparib Alone and With Paclitaxel in Chinese Patients With Advanced Solid Tumour. Phase 1
Terminated NCT01859351 - Phase I Study of WX-037 Alone and in Combination With WX-554 in Solid Tumours Phase 1
Completed NCT01163903 - Pantoprazole With Doxorubicin for Advanced Cancer Patients With Extension Cohort of Patients With Solid Tumours Phase 1
Recruiting NCT05804526 - A Study of RC88 Combined With Sintilimab for Advanced Solid Tumours Phase 1/Phase 2